Bremelanotide: new drug for the treatment of hypoactive sexual desire disorder — VialBase Research

Summary

Review article covering the pharmacology, clinical development, and approval of bremelanotide (PT-141) for HSDD. Covers the unique central nervous system mechanism of action via melanocortin-4 receptor (MC4R) activation, distinguishing it from peripheral-acting sexual dysfunction treatments.

Key Findings

• Bremelanotide acts centrally via MC4R in the brain — fundamentally different from PDE5 inhibitors
• Modulates neural pathways involved in sexual arousal and desire
• FDA-approved as Vyleesi for HSDD in premenopausal women (June 2019)
• Subcutaneous autoinjector delivery — on-demand use at least 45 min before activity
• Not approved for male erectile dysfunction despite early phase trials showing efficacy
• Development history spans from melanocortin peptide research to FDA approval

Methodology

Narrative review synthesizing Phase 1-3 clinical trial data, pharmacokinetic studies, and post-marketing information for bremelanotide.

Limitations

• Review — no new primary data
• Male sexual dysfunction data not comprehensively covered
• Long-term safety data beyond clinical trial periods limited
• Cost and insurance coverage barriers to adoption not discussed
• Off-label use patterns not addressed

Relevance to Content

Useful overview reference for PT-141 content. The central mechanism (brain, not periphery) is a key differentiator for content positioning. Explains why PT-141 works for desire (not just erection) and why it’s relevant for both men and women. The MC4R mechanism helps explain the broader melanocortin system context.

See Also

• Parent compound: PT-141